Literature DB >> 25308798

Vaccine adjuvant uses of poly-IC and derivatives.

Karen A O Martins1, Sina Bavari, Andres M Salazar.   

Abstract

Pathogen-associated molecular patterns (PAMPs) are stand-alone immunomodulators or 'danger signals,' that are increasingly recognized as critical components of many modern vaccines. Polyinosinic-polycytidylic acid (poly-IC) is a synthetic dsRNA that can activate multiple elements of the host defense in a pattern that parallels that of a viral infection. When properly combined with an antigen, it can be utilized as a PAMP-adjuvant, resulting in modulation and optimization of the antigen-specific immune response. We briefly review the preclinical and clinical uses of poly-IC and two poly-IC derivatives, poly-IC12U (Ampligen) and poly-ICLC (Hiltonol), as vaccine adjuvants.

Entities:  

Keywords:  Adaptive immunity; PAMP; TLR3; adjuvant; ampligen; hiltonol; innate immunity; interferons; poly-IC; poly-ICLC; vaccine

Mesh:

Substances:

Year:  2014        PMID: 25308798     DOI: 10.1586/14760584.2015.966085

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  60 in total

1.  Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial.

Authors:  Chrisann Kyi; Vladimir Roudko; Rachel Sabado; Yvonne Saenger; William Loging; John Mandeli; Tin Htwe Thin; Deborah Lehrer; Michael Donovan; Marshall Posner; Krzysztof Misiukiewicz; Benjamin Greenbaum; Andres Salazar; Philip Friedlander; Nina Bhardwaj
Journal:  Clin Cancer Res       Date:  2018-06-27       Impact factor: 12.531

2.  Whole-blood phenotyping to assess alloimmunization status in transfused sickle cell disease patients.

Authors:  Marie Tamagne; Sadaf Pakdaman; Pablo Bartolucci; Anoosha Habibi; Frédéric Galactéros; France Pirenne; Benoît Vingert
Journal:  Blood Adv       Date:  2021-03-09

Review 3.  Turbocharging vaccines: emerging adjuvants for dendritic cell based therapeutic cancer vaccines.

Authors:  Mansi Saxena; Nina Bhardwaj
Journal:  Curr Opin Immunol       Date:  2017-07-18       Impact factor: 7.486

Review 4.  Strategies for designing synthetic immune agonists.

Authors:  Tom Y-H Wu
Journal:  Immunology       Date:  2016-07-11       Impact factor: 7.397

5.  Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1-4.

Authors:  Guillaume B E Stewart-Jones; Gwo-Yu Chuang; Kai Xu; Tongqing Zhou; Priyamvada Acharya; Yaroslav Tsybovsky; Li Ou; Baoshan Zhang; Blanca Fernandez-Rodriguez; Valentina Gilardi; Chiara Silacci-Fregni; Martina Beltramello; Ulrich Baxa; Aliaksandr Druz; Wing-Pui Kong; Paul V Thomas; Yongping Yang; Kathryn E Foulds; John-Paul Todd; Hui Wei; Andres M Salazar; Diana G Scorpio; Bridget Carragher; Clinton S Potter; Davide Corti; John R Mascola; Antonio Lanzavecchia; Peter D Kwong
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-12       Impact factor: 11.205

6.  Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients.

Authors:  Takeshi Ishikawa; Shinichi Kageyama; Yoshihiro Miyahara; Tetsuya Okayama; Satoshi Kokura; Linan Wang; Eiichi Sato; Hideo Yagita; Yoshito Itoh; Hiroshi Shiku
Journal:  Cancer Immunol Immunother       Date:  2021-03-22       Impact factor: 6.968

7.  Engineering of a self-adjuvanted iTEP-delivered CTL vaccine.

Authors:  Shuyun Dong; Tiefeng Xu; Peng Wang; Peng Zhao; Mingnan Chen
Journal:  Acta Pharmacol Sin       Date:  2017-04-17       Impact factor: 6.150

8.  TIGIT blockade enhances tumor response to radiotherapy via a CD103 + dendritic cell-dependent mechanism.

Authors:  Kaikai Zhao; Liyang Jiang; Youjiao Si; Shujie Zhou; Zhaoqin Huang; Xiangjiao Meng
Journal:  Cancer Immunol Immunother       Date:  2022-07-06       Impact factor: 6.968

9.  A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma.

Authors:  Roy Rampling; Sharon Peoples; Paul J Mulholland; Allan James; Omar Al-Salihi; Christopher J Twelves; Catherine McBain; Sarah Jefferies; Alan Jackson; Willie Stewart; Juha Lindner; Sarah Kutscher; Norbert Hilf; Lesley McGuigan; Jane Peters; Karen Hill; Oliver Schoor; Harpreet Singh-Jasuja; Sarah E Halford; James W A Ritchie
Journal:  Clin Cancer Res       Date:  2016-05-25       Impact factor: 12.531

10.  Targeting Toll-Like Receptors for Cancer Therapy.

Authors:  Marc J Braunstein; John Kucharczyk; Sylvia Adams
Journal:  Target Oncol       Date:  2018-10       Impact factor: 4.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.